{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:41:52Z","timestamp":1792456912507,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009794","name":"Breast Cancer Now","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2025,12,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Nearly 40 years ago one of us published a conceptual article arguing the case for studies of breast cancer prevention with tamoxifen. Recent observations on the interaction of plasma oestrogen levels with the preventive effect of the aromatase inhibitor anastrozole make it timely to consider the development of oestrogen-targeted prevention of breast cancer and the evidence upon which that development was made. In this article we review the understanding of the aetiology of breast cancer in the mid-1980s; its subsequent development, including the findings from the adjuvant treatment of early breast cancer with tamoxifen and from the trials that assessed tamoxifen as a preventive agent in women at increased risk. We then focus on results from the comparative trials of aromatase inhibitors (AIs) versus tamoxifen and the extension of the use of AIs in trials for prevention. We describe the relationship between plasma levels of oestradiol and its major protein binder, sex hormone binding globulin, on the development of oestrogen receptor positive breast cancer and how these impact on the preventive effect of the AI, anastrozole, in postmenopausal women. Lastly, we speculate on the potential role of routine measurement of oestradiol in managing risk and achieving prevention of breast cancer.<\/jats:p>","DOI":"10.1038\/s41416-025-03115-0","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T10:24:56Z","timestamp":1758277496000},"page":"1757-1764","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Oestradiol and breast cancer prevention: a 40 year history and contemporary perspective"],"prefix":"10.1038","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7420-7512","authenticated-orcid":false,"given":"Jack","family":"Cuzick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4122-744X","authenticated-orcid":false,"given":"Mitch","family":"Dowsett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"key":"3115_CR1","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3109\/07357909509024914","volume":"135","author":"DV Spicer","year":"1995","unstructured":"Spicer DV, Krecker EA, Pike MC. The endocrine prevention of breast cancer. Cancer Investig. 1995;135:495\u2013504.","journal-title":"Cancer Investig"},{"key":"3115_CR2","first-page":"327","volume":"67","author":"JL Kelsey","year":"1981","unstructured":"Kelsey JL, Fischer DB, Holford TR, LiVoisi VA, Mostow ED, Goldenberg IS, et al. Exogenous estrogens and other factors in the epidemiology of breast cancer. J Natl Cancer Inst. 1981;67:327\u201333.","journal-title":"J Natl Cancer Inst"},{"key":"3115_CR3","unstructured":"Olson JS, Bio of Bernardino Ramazzini 2002; ISBN 978-0-8018-69365"},{"key":"3115_CR4","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/sim.4780060803","volume":"6","author":"D Rigoni-Stern","year":"1987","unstructured":"Rigoni-Stern D. Fatti statistici relativi alle malattic Cancerose Giorn. Prog. Patol. Terap. 1842\/. Translated de Stavola Stats Med 1987;6:881\u20134.","journal-title":"Translated de Stavola Stats Med"},{"key":"3115_CR5","first-page":"315","volume":"41","author":"M Feinlieb","year":"1968","unstructured":"Feinlieb M. Breast cancer and artificial menopause: a cohort study. J Natl Cancer Inst. 1968;41:315\u201329.","journal-title":"J Natl Cancer Inst"},{"key":"3115_CR6","doi-asserted-by":"crossref","unstructured":"Bulbrook RD, Moore JW, Clark GMG, Wang DY, Millis RR, Hayward JL. Relation between risk of breast cancer and biological availability of estradiol in blood: prospective study in Guernsey. Endocrinology of the Breast: Basic and Clinical Aspects. Angeli A, Bradlow HL, Dogliotti L Eds. Ann N Y Acad Sci 1986:464:373-88.","DOI":"10.1111\/j.1749-6632.1986.tb16017.x"},{"key":"3115_CR7","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1093\/jnci\/94.8.606","volume":"94","author":"T Key","year":"2002","unstructured":"Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002;94:606\u201316.","journal-title":"J Natl Cancer Inst"},{"key":"3115_CR8","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3389\/fphar.2017.00620","volume":"8","author":"VM Quirke","year":"2017","unstructured":"Quirke VM. Tamoxifen from failed contraceptive pill to best-selling breast cancer medicine: a case-study, pharmaceutical innovation. Front Pharm. 2017;8:620.","journal-title":"Front Pharm"},{"key":"3115_CR9","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/BF01807278","volume":"11","author":"VC Jordan","year":"1988","unstructured":"Jordan VC. The development of tamoxifen for breast cancer therapy: a tribute to the late Arthur L. Walpole. Breast Cancer Res Treat. 1988;11:197\u2013209.","journal-title":"Breast Cancer Res Treat"},{"key":"3115_CR10","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S0140-6736(85)90338-1","volume":"2","author":"J Cuzick","year":"1985","unstructured":"Cuzick J, Baum M. Tamoxifen and contralateral breast cancer. Lancet. 1985;2:282.","journal-title":"Lancet"},{"key":"3115_CR11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0140-6736(86)90729-4","volume":"1","author":"J Cuzick","year":"1986","unstructured":"Cuzick J, Wang DY, Bulbrook RD. The prevention of breast cancer. Lancet. 1986;1:83\u20136.","journal-title":"Lancet"},{"key":"3115_CR12","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3109\/07357908809082130","volume":"6","author":"TJ Powles","year":"1988","unstructured":"Powles TJ, Davey JB, McKinna A. A feasibility trial of tamoxifen chemoprevention of breast cancer in Great Britain. Cancer Investig. 1988;6:621\u20134.","journal-title":"Cancer Investig"},{"key":"3115_CR13","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/S0140-6736(98)85012-5","volume":"352","author":"TJ Powles","year":"1998","unstructured":"Powles TJ, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet. 1998;352:98\u2013101.","journal-title":"Lancet"},{"key":"3115_CR14","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(02)09962-2","volume":"360","author":"J Cuzick","year":"2002","unstructured":"Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, et al. First results from the International Breast Cancer Intervention Study (IBIS-I). Lancet. 2002;360:817\u201324.","journal-title":"Lancet"},{"key":"3115_CR15","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","volume":"90","author":"B Fisher","year":"1998","unstructured":"Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 1998;90:1371\u201388.","journal-title":"J Natl Cancer Inst"},{"key":"3115_CR16","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1093\/jnci\/dji372","volume":"97","author":"B Fisher","year":"2005","unstructured":"Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Walter M, Cronin WM, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97:1652\u201362.","journal-title":"J Natl Cancer Inst"},{"key":"3115_CR17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0140-6736(98)04394-3","volume":"352","author":"U Veronesi","year":"1998","unstructured":"Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet. 1998;352:93\u20137.","journal-title":"Lancet"},{"key":"3115_CR18","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/0140-6736(93)92865-Q","volume":"342","author":"GC Hard","year":"1993","unstructured":"Hard GC, Williams GM, latropoulos MJ. Tamoxifen and liver cancer. Lancet. 1993;342:444\u20135.","journal-title":"Lancet"},{"key":"3115_CR19","volume":"6","author":"M Ghanavati","year":"2023","unstructured":"Ghanavati M, Khorshidi Y, Shadnoush M, Akbari ME, Ardehali SH, Chavarri-Guerra Y, et al. Tamoxifen use and risk of endometrial cancer in breast cancer patients. Cancer Rep. 2023;6:e1806.","journal-title":"Cancer Rep"},{"key":"3115_CR20","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group, Davies C, Godwin J, Gray R, Clarke M, Cutter D, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 201;378:771-84.","DOI":"10.1016\/S0140-6736(11)60993-8"},{"key":"3115_CR21","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/sim.1668","volume":"23","author":"J Tyrer","year":"2004","unstructured":"Tyrer J, Duffy SW, Cuzick J. Stat Med 2004;23:1111\u201330.","journal-title":"Stat Med"},{"key":"3115_CR22","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1214\/19-STS729","volume":"35","author":"AR Brentnall","year":"2020","unstructured":"Brentnall AR, Cuzick J. Risk models for breast cancer and their validation. Stat Sci. 2020;35:14\u201330.","journal-title":"Stat Sci"},{"key":"3115_CR23","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S1470-2045(14)71171-4","volume":"16","author":"J Cuzick","year":"2015","unstructured":"Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of IBIS-I breast cancer prevention trial. Lancet Oncol. 2015;16:67\u201375.","journal-title":"Lancet Oncol"},{"key":"3115_CR24","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/S0140-6736(03)12342-2","volume":"361","author":"J Cuzick","year":"2003","unstructured":"Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003;361:296\u2013300.","journal-title":"Lancet"},{"key":"3115_CR25","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1093\/jnci\/95.11.779","volume":"95","author":"A Decensi","year":"2003","unstructured":"Decensi A, Robertson C, Viale G, Pigatto F, Johansson H, Kisanga ER, et al. A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst. 2003;95:779\u201390.","journal-title":"J Natl Cancer Inst"},{"key":"3115_CR26","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1200\/JCO.18.01779","volume":"37","author":"A DeCensi","year":"2019","unstructured":"DeCensi A, Puntoni M, Guerrieri-Gonzaga A, Caviglia S, Avino F, Cortesi L, et al. Randomized placebo controlled trial of low-dose tamoxifen to prevent local and contralateral recurrence in breast intraepithelial neoplasia. J Clin Oncol. 2019;37:1629\u201337.","journal-title":"J Clin Oncol"},{"key":"3115_CR27","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.1200\/JCO.22.02900","volume":"41","author":"M Lazzaroni","year":"2023","unstructured":"Lazzaroni M, Puntoni M, Guerrieri-Gonzaga A, Serrano D, Boni L, Webber TB, et al. A randomized placebo controlled trial of low-dose tamoxifen to prevent recurrence in breast noninvasive neoplasia: a 10-year follow-up of TAM-01 study. J Clin Oncol 2023;41:3116\u201321.","journal-title":"J Clin Oncol"},{"key":"3115_CR28","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1200\/JCO.20.02598","volume":"39","author":"M Eriksson","year":"2021","unstructured":"Eriksson M, Eklund M, Borgquist S, Hellgren R, Margolin S, Thoren L, et al. Low-dose tamoxifen for mammographic density reduction: a randomized controlled trial. J Clin Oncol. 2021;39:1899\u2013908.","journal-title":"J Clin Oncol"},{"key":"3115_CR29","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1095\/biolreprod18.3.365","volume":"18","author":"AM Brodie","year":"1978","unstructured":"Brodie AM, Wu JT, Marsh DA, Brodie HJ. Aromatase inhibitors III. Studies on the antifertility effect of 4-acetoxy-4-androstene-3,17-dione. Biol Reprod. 1978;18:365\u201370.","journal-title":"Biol Reprod"},{"key":"3115_CR30","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1210\/endo-100-6-1684","volume":"100","author":"AM Brodie","year":"1977","unstructured":"Brodie AM, Schwarzel WC, Shaikh AA, Brodie H. The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3,17-dione, on estrogen-dependent processes in reproduction and breast cancer. J Endocrinol. 1977;100:1684\u201395.","journal-title":"J Endocrinol"},{"key":"3115_CR31","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/S0140-6736(84)92795-8","volume":"2","author":"RC Coombes","year":"1984","unstructured":"Coombes RC, Goss P, Dowsett M, Gazet JC, Brodie A. 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. Lancet. 1984;2:1237\u20139.","journal-title":"Lancet"},{"key":"3115_CR32","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1097\/00000658-197805000-00004","volume":"187","author":"SA Wells Jr","year":"1978","unstructured":"Wells SA Jr, Santen RJ, Lipton A, Haagensen DE Jr, Ruby EJ, Harvey H, et al. Medical adrenalectomy with aminoglutethimide: clinical studies in postmenopausal patients with metastatic breast carcinoma. Ann Surg 1978;187:475\u201384.","journal-title":"Ann Surg"},{"key":"3115_CR33","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/bjc.1983.100","volume":"47","author":"AL Harris","year":"1983","unstructured":"Harris AL, Dowsett M, Smith IE, Jeffcoate SL. Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer. Br J Cancer. 1983;47:621\u20137.","journal-title":"Br J Cancer"},{"key":"3115_CR34","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1016\/S0140-6736(02)09088-8","volume":"359","author":"M Baum","year":"2002","unstructured":"Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359:2131\u201339.","journal-title":"Lancet"},{"key":"3115_CR35","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","volume":"365","author":"A Howell","year":"2005","unstructured":"Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al. Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years\u2019 adjuvant treatment for breast cancer. Lancet. 2005;365:60\u20132.","journal-title":"Lancet"},{"key":"3115_CR36","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/S1470-2045(10)70257-6","volume":"11","author":"J Cuzick","year":"2010","unstructured":"Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11:1135\u201341.","journal-title":"Lancet Oncol"},{"key":"3115_CR37","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1097\/00000421-200308001-00005","volume":"26","author":"PE Goss","year":"2003","unstructured":"Goss PE. Emerging role of aromatase inhibitors in the adjuvant setting. Am J Clin Oncol. 2003;26:S27\u201333.","journal-title":"Am J Clin Oncol"},{"key":"3115_CR38","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3816\/CBC.2008.n.049","volume":"8","author":"PE Goss","year":"2008","unstructured":"Goss PE, Muss HB, Ingle JN, Whelan TJ, Wu M. Extended adjuvant endocrine therapy in breast cancer: current status and future directions. Clin Breast Cancer. 2008;8:411\u20137.","journal-title":"Clin Breast Cancer"},{"key":"3115_CR39","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1056\/NEJMoa052258","volume":"353","author":"B Th\u00fcrlimann","year":"2005","unstructured":"Breast International Group (BIG) 1-98 Collaborative Group, Th\u00fcrlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353:2747\u201357.","journal-title":"N Engl J Med"},{"key":"3115_CR40","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1038\/bjc.1996.531","volume":"74","author":"J Geisler","year":"1996","unstructured":"Geisler J, King N, Dowsett M, Ottestad L, Lundgren S, Walton P, et al. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer. 1996;74:1286\u201391.","journal-title":"Br J Cancer"},{"key":"3115_CR41","first-page":"2089","volume":"4","author":"J Geisler","year":"1998","unstructured":"Geisler J, King N, Anker G, Ornati G, Di Salle E, L\u00f8nning PE, et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res. 1998;4:2089\u201393.","journal-title":"Clin Cancer Res"},{"key":"3115_CR42","first-page":"1511","volume":"1","author":"M Dowsett","year":"1995","unstructured":"Dowsett M, Jones A, Johnston SR, Jacobs S, Trunet P, Smith IE. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res. 1995;1:1511\u20135.","journal-title":"Clin Cancer Res"},{"key":"3115_CR43","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","volume":"386","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG","year":"2015","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386:1341\u201352.","journal-title":"Lancet"},{"key":"3115_CR44","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S0140-6736(13)62292-8","volume":"383","author":"J Cuzick","year":"2014","unstructured":"Cuzick J, Sestak I, Forbes JF, Dowsett M, Jill Knox J, Cawthorn S, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet. 2014;383:1041\u20138.","journal-title":"Lancet"},{"key":"3115_CR45","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(19)32955-1","volume":"395","author":"J Cuzick","year":"2020","unstructured":"Cuzick J, Sestak I, Forbes JF, Dowsett M, Cawthorn, Mansel RE, et al. Use of anastrozole for breast cancer prevention (IBIS-II). Lancet. 2020;395:117\u201322.","journal-title":"Lancet"},{"key":"3115_CR46","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1056\/NEJMoa1103507","volume":"364","author":"PE Goss","year":"2011","unstructured":"Goss PE, Ingle JN, Al\u00e9s-Mart\u00ednez JE, Chlebowski RT, Wactawski-Wende J, Anne McTiernan A, et al. Exemestane for breast-cancer prevention in postmenopausal women. N. Engl J Med. 2011;364:2381\u201391.","journal-title":"N. Engl J Med"},{"key":"3115_CR47","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1093\/jnci\/djj376","volume":"98","author":"AH Eliassen","year":"2006","unstructured":"Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett M, et al. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst. 2006;98:1406\u201315.","journal-title":"J Natl Cancer Inst"},{"key":"3115_CR48","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/ijc.28528","volume":"134","author":"R Kaaks","year":"2014","unstructured":"Kaaks R, Tik K, Sookthai D, Schock H, Theron J, Tj\u00f8nneland A, et al. Premenopausal serum sex hormone levels in relation to breast cancer risk, overall and by hormone receptor status. Int J Cancer. 2014;134:1947\u201357.","journal-title":"Int J Cancer"},{"key":"3115_CR49","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41416-021-01392-z","volume":"125","author":"S Tin Tin","year":"2021","unstructured":"Tin Tin S, Reeves GK, Key TJ. Endogenous hormones and risk of invasive breast cancer in pre- and post-menopausal women. Br J Cancer. 2021;125:126\u201334.","journal-title":"Br J Cancer"},{"key":"3115_CR50","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1001\/jama.287.2.216","volume":"287","author":"SR Cummings","year":"2002","unstructured":"Cummings SR, Duong T, Kenyon E, Cauley JA, Whitehead M, Krueger KA. Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA. 2002;287:216\u201320.","journal-title":"JAMA"},{"key":"3115_CR51","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1093\/jnci\/djj011","volume":"98","author":"MS Beattie","year":"2006","unstructured":"Beattie MS, Costantino JP, Cummings SR, Wickerham DL, Vogel VG, Dowsett M, et al. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP breast cancer prevention trial (P-1). J Natl Cancer Inst. 2006;98:110\u20135.","journal-title":"J Natl Cancer Inst"},{"key":"3115_CR52","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/S1470-2045(23)00578-8","volume":"25","author":"J Cuzick","year":"2024","unstructured":"Cuzick J, Chu K, Keevil B, Brentnall AR, Howell A, Zdenkowski N, et al. Effect of baseline oestradiol serum concentration on the efficacy of anastrozole for preventing breast cancer in postmenopausal women at high risk. Lancet Oncol. 2024;25:108\u201316.","journal-title":"Lancet Oncol"},{"key":"3115_CR53","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1177\/0004563213501478","volume":"51","author":"LJ Owen","year":"2014","unstructured":"Owen LJ, Wu FC, Keevil BG. A rapid direct assay for the routine measurement of oestradiol and oestrone by liquid chromatography tandem mass spectrometry. Ann Clin Biochem. 2014;51:360\u201367.","journal-title":"Ann Clin Biochem"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03115-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03115-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03115-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T22:01:55Z","timestamp":1765317715000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03115-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":53,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,28]]}},"alternative-id":["3115"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-03115-0","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]},"assertion":[{"value":"1 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}